Olaf Valverde Mordt

Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial

Victor Kande Betu Ku Mesu, Wilfried Mutombo Kalonji, Clélia Bardonneau et al. · The Lancet · 2017 · 269 citations

Veterinary Medicine, Biology, Infectious Diseases +15

Efficacy and safety of acoziborole in patients with human African trypanosomiasis caused by Trypanosoma brucei gambiense: a multicentre, open-label, single-arm, phase 2/3 trial

Victor Kande Betu Kumeso, Wilfried Mutombo Kalonji, Sandra Rembry et al. · The Lancet Infectious Diseases · 2022 · 116 citations · Full text

Veterinary Medicine, Infectious Diseases, Pharmacology +17

Determination of an Optimal Dosing Regimen for Fexinidazole, a Novel Oral Drug for the Treatment of Human African Trypanosomiasis: First-in-Human Studies

Antoine Tarral, Séverine Blesson, Olaf Valverde Mordt et al. · Clinical Pharmacokinetics · 2014 · 97 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +15

Oral fexinidazole for stage 1 or early stage 2 African Trypanosoma brucei gambiense trypanosomiasis: a prospective, multicentre, open-label, cohort study

Victor Kande Betu Ku Mesu, Wilfried Mutombo Kalonji, Clélia Bardonneau et al. · The Lancet Global Health · 2021 · 56 citations · Full text

Pharmacy, Infectious Diseases, Pharmacology +16

In-Hospital Safety in Field Conditions of Nifurtimox Eflornithine Combination Therapy (NECT) for T. b. gambiense Sleeping Sickness

Caecilia Schmid, Andrea Kuemmerle, Johannes Blum et al. · PLoS neglected tropical diseases · 2012 · 48 citations · Full text

Pharmacy, Infectious Diseases, Pharmacology +14